Search Results

You are looking at 11 - 20 of 388 items for :

  • Refine by Access: All x
Clear All
Full access


David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Michael Anne Markiewicz, Lida Nabati, Carli Nesheiwat, Hope S. Rugo, Steven M. Sorscher, Lisa Stucky-Marshal, Barbara Todaro, and Susan Urba

– 1752 . 5 Morran C Smith DC Anderson DA . Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics . Br Med J 1979 ; 1 : 1323 – 1324 . 6 Jenns K . Importance of nausea

Full access

NCCN Guidelines Insights: Antiemesis, Version 2.2017

Michael J. Berger, David S. Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J. Bierman, Debra Brandt, Dawn E. Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D. Kloth, Ruth Lagman, Dean Lim, Charles Loprinzi, Cynthia X. Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M. Nabell, Kim Noonan, Eric Roeland, Hope S. Rugo, Lee S. Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G. Urba, Dorothy A. Shead, and Miranda Hughes

management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. Overview Vomiting (emesis) and nausea induced by systemic or radiation therapy (RT) can significantly affect a patient

Full access

Are All 5-HT3 Receptor Antagonists the Same?

Robert McNulty

1998 ; 4 : 52 – 58 . 9. Perez EA Hesketh P Sandbach J . Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double

Full access

Obstacles to the Implementation of Antiemetic Guidelines

Steven M. Grunberg

. 8 American Society of Health-System Pharmacists . ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery . Am J Health

Full access

A Review of the Symptomatic Management of Malignant Gliomas in Adults

Umang Shah and Tara Morrison

brain metastasis undergoing whole-brain radiation suggests possible benefit from the use of memantine. 31 Nausea and Vomiting Chemotherapy-induced nausea and vomiting (CINV) is a frequent problem in oncology patients The primary chemotherapy used

Full access

EPR19-74: Risk of Cabozantinib-Associated Gastrointestinal and Hepatic Toxicities in Patients With Metastatic Solid Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Anita Sultan, Sriman Swarup, Francis Mogollon-Duffo, Ye Aung, Yin M. Myat, Myo H. Zaw, Rachana Yendala, Nicholas D’Cunha, and Kyaw Z. Thein

used cabozantinib while the control arm utilized everolimus or placebo or prednisone. The relative risks of all-grade side effects were as follows: diarrhea, 2.495 (95% CI: 2.149–2.897, P <.0001); nausea, 1.849 (95% CI: 1.649–2.072; P <.0001

Full access

Prevention of Emesis from Multiple-Day and High-Dose Chemotherapy Regimens

Rudolph M. Navari

current practice in Canada . Supp Cancer Therapy 2005 ; 2 : 181 – 187 . 3. Osoba D Zee B Warr D . Effect of post-chemotherapy nausea and vomiting on health related quality of life . Support Care Cancer 1997 ; 5 : 307 – 313 . 4

Full access

Cannabinoids for Symptom Management and Cancer Therapy: The Evidence

Mellar P. Davis

benefits. Marijuana, the dried leaves and flowers of the hemp plant that are smoked as a drug, was on the American pharmacopeia until 1944. It returned in the form of delta(9)-THC (dronabinol) in 1986, approved for treatment of chemotherapy-induced nausea

Full access

Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer

Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le

every outpatient visit using the ESAS-r, with targeted EPC referral according to an algorithm based on symptom severity ( Figure 1 ). The ESAS-r assesses the severity of 9 common cancer symptoms (pain, fatigue, drowsiness, nausea, anxiety, depression

Full access

CLO19-025: Treatment Discontinuation Due to Adverse Events and the Risk of Gastrointestinal Toxicities in Patients With Hematologic Malignancies Treated With Ibrutinib

Meily Arevalo, Myo H. Zaw, Anita Sultan, Sriman Swarup, Nay N. Yee, Wai L. Thein, Myet M. Zin, Nusrat Jahan, and Kyaw Z. Thein

) for treatment discontinuation was 0.740 (95% CI: 0.385–1.423; P =.367). The pooled RR of all-grade side effects were as follows: diarrhea, 1.955 (95% CI: 1.304–2.933; P =.001); nausea, 1.038 (95% CI: 0.702–1.534; P =.852); vomiting, 1.048 (95% CI: 0